<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104569</url>
  </required_header>
  <id_info>
    <org_study_id>37℃ Contrast Agent in ERCP</org_study_id>
    <nct_id>NCT03104569</nct_id>
  </id_info>
  <brief_title>Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma</brief_title>
  <official_title>Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic
      contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde
      cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, the common used contrast agent in ERCP is composed of ionic and non-ionic type,
      and the latter's advantages lie in its slighter toxic-and-side effect and favorable security.
      When heated to 37℃, the 20 ℃ contrast agents would be diluted to 50% consistency, then a
      shorter time period of its intravascular and other intracavitary stay would add to less cell
      damage. And the applications of heated non-ionic contrast agents could be found in computed
      tomography angiography(CTA), hysterosalpingography (HSG) and cystourethrography, and
      consequently the patients with the intervention of heated non-ionic contrast agents felt more
      comfortable and fewer adverse reactions could be observed. Nevertheless, heated contrast
      agent was rarely reported to act in ERCP. It's theoretically possible that its heat-reduced
      lower mucosity could help the contrast agent itself to drainage, so that the incidence of
      cholangeitis could be under control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Acute cholangitis</measure>
    <time_frame>2 weeks</time_frame>
    <description>Acute cholangitis is defined if patients experienced abdominal pain, high fever(over 38.5℃), or chill after procedure in 2 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ease of injection</measure>
    <time_frame>During procedures</time_frame>
    <description>The ease of contrast agent injection has been considered by ERCP assistant, a questionnaire is required to assign by the assistant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>4 days</time_frame>
    <description>9 parameter will be collected in day 2 and day 4 after procedures. Abnormal in Total bilirubin (TBIL), White Blood Count (WBC), N%,Platelet( PLT), Procalcitonin(PCT) or C-reactive protein(CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and Gamma - glutamyl transpeptidase (GGT) required to be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>intraoperative</time_frame>
    <description>Total time of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>X-ray exposure time</measure>
    <time_frame>intraoperative</time_frame>
    <description>The total time of X-ray exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Post-ERCP pancreatitis</measure>
    <time_frame>1 months</time_frame>
    <description>Post-ERCP pancreatitis is defined if patients experienced abdominal pain for more than 24h after ERCP, accompanying with amylase or lipase more than 3 times equal to the upper limit of normal value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cholangitis</condition>
  <arm_group>
    <arm_group_label>Injection of 37℃ contrast agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection of normal contrast agent</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection of 37℃ contrast agent</intervention_name>
    <description>Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent</description>
    <arm_group_label>Injection of 37℃ contrast agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;

          -  Age: 18~90 years old;

          -  Underwent diagnostic and therapeutic ERCP;

        Exclusion Criteria:

          -  Coagulation dysfunction(INR＞1.3) or/and low peripheral blood platelet count （PLT
             &lt;50x10^9/L）;

          -  Preoperative acute cholangitis;

          -  Preoperative acute pancreatitis;

          -  Preoperative hemobilia or hemorrhage of digestive tract;

          -  Preoperative liver failure;

          -  Combined with Mirizzi syndrome and intrahepatic bile duct stones;

          -  Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas,
             gallbladder carcinoma;

          -  Biliary-duodenal fistula confirmed during ERCP;

          -  A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a
             history of cholangioenterostomy including cholangio-jejunostomy and side to side
             anastomosis of the bile duct and duodenum;

          -  Previous ERCP;

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xun Li, M.D., Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenbo Meng, M.D., Ph. D.</last_name>
    <phone>+8613919177177</phone>
    <email>mengwb@lzu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xun Li, M.D., Ph. D.</last_name>
    <phone>+8613993138612</phone>
    <email>drlixun@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first hospital of Lanzhou university</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wence Zhou, M. D.</last_name>
      <phone>+8609318356919</phone>
      <email>zhouwc129@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenbo Meng, M. D.</last_name>
      <phone>+8609318356213</phone>
      <email>mengwb@lzu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Xi 'an jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Sun, M. D.</last_name>
      <phone>+86 13891813691</phone>
      <email>sunhaoxjfy@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Nankai Hospital</name>
      <address>
        <city>Tianjin Shi</city>
        <state>Tianjin</state>
        <zip>300100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenyu Wang, M. D.</last_name>
      <phone>+86 15302021661</phone>
      <email>Wangzytj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xun Li</investigator_full_name>
    <investigator_title>M.D., Ph. D, Director.</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>Contrast agent</keyword>
  <keyword>Hilar cholangiocarcinoma</keyword>
  <keyword>Cholangitis</keyword>
  <keyword>Nonionic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

